Site for AALL1732:: A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494 NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk Adapted Post-Induction Therapy for High-Risk B-ALL Mixed Phenotype Acute Leukemia and Disseminated B-LLy

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    B-all
    B-lly; Mpal
  • Age: Between 1 Year(s) - 24 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) White blood cell count (WBC) criteria for patients with B-ALL (within 7 days prior to the start of protocol-directed systemic therapy): ?Age 1-9.99 years: WBC >= 50,000/uL ?Age 10-24.99 years: Any WBC ?Age 1-9.99 years: WBC < 50,000/uL with: ?Testicular leukemia ?CNS leukemia (CNS3) ?Steroid pretreatment. •White blood cell count (WBC) criteria for patients with MPAL (within 7 days prior to the start of protocol-directed systemic therapy): ?Age 1-24.99 years: any WBC.

You may not be eligible for this study if the following are true:

  • 1) Patients with Down Syndrome are not eligible. 2) Patients with known Charcot-Marie-Tooth disease. 3) Patients with Acute Undifferentiated Leukemia (AUL) are not eligible.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.